Microdevice study for advanced ovarian or related cancers
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 1 study tests a tiny implanted device placed in the abdomen to help evaluate or treat advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you’d also have additional tests and surgery as part of your usual care plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with advanced stage (III–IV) ovarian, fallopian tube, or peritoneal cancer, confirmed or strongly suspected.
- Your cancer care team plans for surgery (either first surgery, surgery after chemotherapy, or surgery to reassess a recurrence).
- You must be well enough for both a needle-based procedure (to place the microdevice) and standard surgery, as judged by your cancer doctors.
- Recent bloodwork must be safe for procedures (for example, white blood cell and platelet counts high enough, and clotting tests not too abnormal).
- You must have had an abdominal/pelvic CT scan within the last 4 weeks to confirm there is a reachable tumor spot for the device.
- You must be able to get the device placed safely and it can be removed during your planned surgery/laparoscopy without harming needed tissue.
- If you could become pregnant, you must have a negative pregnancy test before the device is placed.
- You must be willing to sign consent and to do extra research genetic testing (with genetic data shared in NIH databases).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial uses a small piece of your cancer tissue (taken during surgery) to grow 'mini-tumors' in the lab. These help doctors find which treatments might work best for you. It is for people with advanced serous ovarian cancer.
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.